ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

XBIO Xenetic Biosciences Inc

4.0899
0.314 (8.32%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 667
Bid Price 3.77
Ask Price 4.93
News -
Day High 4.1299

Low
2.55

52 Week Range

High
5.97

Day Low 3.75
Share Name Share Symbol Market Stock Type
Xenetic Biosciences Inc XBIO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.314 8.32% 4.0899 19:00:00
Open Price Low Price High Price Close Price Previous Close
3.75 3.75 4.1299 4.0899 3.7759
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
20 667 US$ 4.04 US$ 2,696 - 2.55 - 5.97
Last Trade Type Quantity Price Currency
15:00:00 2 US$ 3.81 USD

Xenetic Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
6.3M 1.54M - 2.54M -4.14M -2.68 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Xenetic Biosciences News

Date Time Source News Article
2/12/202408:15Edgar (US Regulatory)Form 8-K - Current report
12/18/202316:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/18/202316:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
12/08/202316:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/08/202316:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/08/202316:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/08/202316:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/08/202316:00Edgar (US Regulatory)Form 8-K - Current report
11/13/202316:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statements
11/13/202307:30Edgar (US Regulatory)Form 8-K - Current report
11/09/202316:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
9/18/202311:21Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No XBIO Message Board. Create One! See More Posts on XBIO Message Board See More Message Board Posts

Historical XBIO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week4.064.303.743.812,5690.02990.74%
1 Month3.854.743.744.346,8810.23996.23%
3 Months3.664.743.33014.165,7470.429911.75%
6 Months3.064.742.86963.865,1991.0333.66%
1 Year4.6215.972.553.6417,122-0.5311-11.49%
3 Years19.6056.802.40129.40941,726-15.51-79.13%
5 Years14.30168.8952.40126.49746,185-10.21-71.40%

Xenetic Biosciences Description

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer.

Your Recent History

Delayed Upgrade Clock